Skip to content
Search

Latest Stories

UK minister Cleverly says full contest for new PM is required

“I think that everyone recognises the incentive of doing that properly and professionally but quickly, so that we can get some certainty.”

UK minister Cleverly says full contest for new PM is required

British Education Secretary James Cleverly said on Friday he did not agree with calls for Prime Minister Boris Johnson to stand down immediately, saying the Conservative Party needed to hold a full contest to find the best leader.

"(Johnson) remains prime minister until a new prime minister is found, that's how our system works," he told Sky News.


"I think that everyone recognises the incentive of doing that properly and professionally but quickly, so that we can get some certainty."

Johnson quit on Thursday, saying he would stay in place until a successor was found, a process that can take several months. Cleverly said he would not run for the leadership.

Cleverly, who took charge of the education department on Thursday, rejected former prime minister John Major's call to expedite appointing a new leader by cutting out the final vote by Conservative party members across the country.

"So John Major has an opinion, I disagree with that," he said. "I think testing the ability of a candidate to reach out beyond the Westminster bubble is incredibly important, so I think it's an important part of the process."

(Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less